Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL CHRISTOPHER JOYCE

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1700045713
CMS profile
77679
Location
SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$92,566.63

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $62,882.90 44
ABBVIE INC. $16,528.88 15
SANOFI US SERVICES INC. $10,187.00 6
Incyte Corporation $2,845.09 4
Regeneron Healthcare Solutions, Inc. $67.81 2
Arcutis Biotherapeutics, Inc. $34.22 1
PFIZER INC. $20.73 1

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL CHRISTOPHER JOYCE

NPI 1700045713 · CMS profile ID 77679

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $92,566.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $30.2912/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141849 CMS
ABBVIE INC. $19.1811/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202141847 CMS
ABBVIE INC. $3,750.0011/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202141845 CMS
GENZYME CORPORATION $250.0010/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200561 CMS
ABBVIE INC. $111.3510/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141843 CMS
GENZYME CORPORATION $8,967.0010/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200523 CMS
GENZYME CORPORATION $424.9110/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200525 CMS
GENZYME CORPORATION $324.5410/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200527 CMS
GENZYME CORPORATION $100.5010/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200545 CMS
GENZYME CORPORATION $4,697.0010/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200547 CMS
GENZYME CORPORATION $268.5110/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200549 CMS
GENZYME CORPORATION $162.5210/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200551 CMS
GENZYME CORPORATION $1,250.0009/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200517 CMS
GENZYME CORPORATION $250.0009/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200565 CMS
GENZYME CORPORATION $48.6108/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200507 CMS
ABBVIE INC. $234.8108/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202141841 CMS
ABBVIE INC. $3,750.0008/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202141839 CMS
Incyte Corporation $2,400.0008/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226139671 CMS
Incyte Corporation $250.0508/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226139677 CMS
SANOFI US SERVICES INC. $1,336.0007/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1233200539 CMS
ABBVIE INC. $44.1807/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141837 CMS
Arcutis Biotherapeutics, Inc. $34.2207/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252349811 CMS
GENZYME CORPORATION $50.3707/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200497 CMS
ABBVIE INC. $113.5307/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141835 CMS
Incyte Corporation $180.4607/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226021717 CMS
GENZYME CORPORATION $812.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200501 CMS
ABBVIE INC. $254.6807/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202141833 CMS
PFIZER INC. $20.7306/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228917815 CMS
GENZYME CORPORATION $250.0006/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200503 CMS
ABBVIE INC. $3,750.0006/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202141831 CMS
Regeneron Healthcare Solutions, Inc. $35.4806/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212953738 CMS
GENZYME CORPORATION $250.0005/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200559 CMS
ABBVIE INC. $15.1705/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141829 CMS
GENZYME CORPORATION $5.6205/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200489 CMS
GENZYME CORPORATION $6,496.0005/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200509 CMS
GENZYME CORPORATION $249.6605/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200511 CMS
GENZYME CORPORATION $308.9605/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200513 CMS
GENZYME CORPORATION $86.0005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200567 CMS
GENZYME CORPORATION $22.4005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200569 CMS
GENZYME CORPORATION $37.8005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200571 CMS
GENZYME CORPORATION $39.3004/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200485 CMS
GENZYME CORPORATION $3,843.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200487 CMS
GENZYME CORPORATION $8,967.0004/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200473 CMS
GENZYME CORPORATION $530.8204/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200475 CMS
GENZYME CORPORATION $2,960.8004/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200477 CMS
GENZYME CORPORATION $52.5904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200479 CMS
GENZYME CORPORATION $5,551.0004/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200481 CMS
GENZYME CORPORATION $530.8004/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200483 CMS
GENZYME CORPORATION $6.9304/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200467 CMS
GENZYME CORPORATION $5.4604/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200459 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $700.40 2
PY2020 $2,376.00 1
PY2021 $2,246.65 3
PY2022 $2,632.70 9
PY2023 $23,671.61 40
PY2024 $79,055.13 79
PY2025 $92,566.63 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,750.00 4
PY2025 Principal investigator $694,810.55 184
PY2024 Recipient $7,148.03 20
PY2024 Principal investigator $657,792.45 167
PY2023 Recipient $3,281.97 14
PY2023 Principal investigator $421,779.06 92
PY2022 Recipient $1,517.38 3
PY2022 Principal investigator $234,287.76 66
PY2021 Principal investigator $111,180.61 56
PY2020 Principal investigator $343,493.78 70
PY2019 Principal investigator $4,975.53 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $4,603.35 12/30/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136547
Principal investigator 1 AbbVie Inc. $1,752.79 12/02/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136541
Principal investigator 1 PFIZER INC. $1,300.00 11/25/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742927725
Principal investigator 1 PFIZER INC. $750.00 11/20/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 742927727
Principal investigator 1 PFIZER INC. $6,900.40 11/18/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742927136
Principal investigator 1 PFIZER INC. $2,311.40 11/17/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742927133
Principal investigator 1 PFIZER INC. $2,600.00 11/11/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742928011
Principal investigator 1 AbbVie Inc. $4,852.45 10/29/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136527
Principal investigator 1 PFIZER INC. $59,979.40 10/28/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742927431
Principal investigator 1 PFIZER INC. $2,178.80 10/28/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742928600
Principal investigator 1 PFIZER INC. $2,502.50 10/17/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742927487
Principal investigator 1 PFIZER INC. $1,686.10 10/16/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742928603
Principal investigator 1 Eli Lilly and Company $10,066.22 10/08/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 728728769
Principal investigator 1 PFIZER INC. $1,300.00 10/02/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742927483
Principal investigator 1 AbbVie Inc. $9,385.71 10/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136521
Principal investigator 1 PFIZER INC. $4,304.30 10/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742927427
Principal investigator 1 PFIZER INC. $6,142.50 09/23/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742927723
Principal investigator 1 PFIZER INC. $70.52 09/22/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742927797
Principal investigator 1 PFIZER INC. $1,300.00 09/19/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742927919
Principal investigator 1 PFIZER INC. $5,892.00 09/18/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742927635
Principal investigator 1 PFIZER INC. $5,119.40 09/17/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742927633
Principal investigator 1 PFIZER INC. $1,000.00 09/17/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742927801
Principal investigator 1 PFIZER INC. $443.30 09/17/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742928013
Principal investigator 1 PFIZER INC. $1,649.04 09/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742927803
Principal investigator 1 AbbVie Inc. $1,761.57 08/31/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136509
Principal investigator 1 PFIZER INC. $443.30 08/28/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742927139
Principal investigator 1 PFIZER INC. $1,300.00 08/19/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742932913
Principal investigator 1 PFIZER INC. $8,370.70 08/18/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742928041
Principal investigator 1 PFIZER INC. $7,594.50 08/18/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742928597
Principal investigator 1 AbbVie Inc. $1,752.79 08/03/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136499
Principal investigator 1 PFIZER INC. $3,662.10 07/31/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742928033
Principal investigator 1 PFIZER INC. $650.00 07/31/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742933319
Principal investigator 1 PFIZER INC. $2,502.50 07/17/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742932683
Principal investigator 1 PFIZER INC. $4,980.40 07/16/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742928357
Principal investigator 1 PFIZER INC. $4,753.84 07/15/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742928037
Principal investigator 1 PFIZER INC. $1,235.00 07/04/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742932915
Principal investigator 1 PFIZER INC. $1,054.00 07/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742927915
Principal investigator 1 PFIZER INC. $403.65 07/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742933315
Principal investigator 1 AbbVie Inc. $2,136.87 06/30/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136485
Principal investigator 1 PFIZER INC. $2,698.48 06/17/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742933239
Principal investigator 1 PFIZER INC. $3,061.56 06/13/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742936217
Principal investigator 1 AbbVie Inc. $13,920.71 06/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136471
Principal investigator 1 PFIZER INC. $228.48 05/29/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936685
Principal investigator 1 PFIZER INC. $10,091.74 05/28/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742936213
Principal investigator 1 PFIZER INC. $1,723.16 05/16/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936767
Principal investigator 1 PFIZER INC. $8,168.29 05/15/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742935979
Principal investigator 1 PFIZER INC. $18,768.80 05/15/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742936007
Principal investigator 1 PFIZER INC. $2,470.00 05/15/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936681
Principal investigator 1 PFIZER INC. $2,362.46 05/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936761
Principal investigator 1 PFIZER INC. $734.12 04/30/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 742936679
Principal investigator 1 PFIZER INC. $1,339.98 04/30/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936693
Principal investigator 1 PFIZER INC. $5,167.26 04/29/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742935866
Principal investigator 1 PFIZER INC. $593.67 04/29/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936807
Principal investigator 1 PFIZER INC. $6,903.64 04/23/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936803
Principal investigator 1 PFIZER INC. $16,933.10 04/21/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742936001
Principal investigator 1 PFIZER INC. $12,781.04 04/21/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742936005
Principal investigator 1 PFIZER INC. $500.00 03/19/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742935859
Principal investigator 1 PFIZER INC. $18,999.25 03/18/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742935863
Principal investigator 1 PFIZER INC. $1,235.00 03/12/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936687
Principal investigator 1 PFIZER INC. $1,693.18 03/11/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936763
Principal investigator 1 AbbVie Inc. $1,324.85 03/02/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 No dispute reported 06/30/2026 721136433
Principal investigator 1 PFIZER INC. $3,401.64 02/28/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF04965842 MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742932457
Principal investigator 1 PFIZER INC. $1,235.00 02/28/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742932679
Principal investigator 1 PFIZER INC. $5,200.00 02/28/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA No dispute reported 06/30/2026 742936667
Principal investigator 1 PFIZER INC. $8,100.00 02/27/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 742936713
Principal investigator 1 PFIZER INC. $2,100.12 02/25/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936673
Principal investigator 1 PFIZER INC. $5,514.28 02/25/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA AA SUBJECTS WITH 50 OR GREATER SCALP HAIR LOSS No dispute reported 06/30/2026 742936709
Principal investigator 1 PFIZER INC. $1,296.75 02/04/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742932373
Principal investigator 1 PFIZER INC. $2,698.48 02/04/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742932459
Principal investigator 1 PFIZER INC. $1,557.34 02/01/2020 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742936715